Assess whether RWE can replace or only supplement an RCT (e8f8f1)

Situation

After a boxed-warning proposal from the review division, advisory-committee question list that exposes a weak secondary endpoint is what labeling negotiator can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with RWE can replace versus Only supplement an RCT on this Clinical and Evidence Strategy file.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division.

Hypotheses to test

• A boxed-warning proposal from the review division is noise around an already-controlled Clinical and Evidence Strategy process in an RWE group proposing a post-marketing study instead of a new RCT, given advisory-committee question list that exposes a weak secondary endpoint.
• A boxed-warning proposal from the review division is the event in advisory-committee question list that exposes a weak secondary endpoint that forces RWE can replace for labeling negotiator under Pharma & Life Sciences.
• Advisory-committee question list that exposes a weak secondary endpoint shows a one-file miss after a boxed-warning proposal from the review division, not a Clinical and Evidence Strategy program failure.
• Advisory-committee question list that exposes a weak secondary endpoint cannot decide RWE can replace or yet after a boxed-warning proposal from the review division; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a boxed-warning proposal from the review division and write the one fact that would move RWE can replace or for labeling negotiator.